Novel mutations of PKD genes in the Czech population with autosomal dominant polycystic kidney disease.

Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary renal disorder caused by mutation in either one of two genes, PKD1 and PKD2. High structural and sequence complexity of PKD genes makes the mutational diagnostics of ADPKD challenging. The present study is the first detailed analysis of both PKD genes in a cohort of Czech patients with ADPKD using High Resolution Melting analysis (HRM) and Multiplex Ligation-dependent Probe Amplification (MLPA).

[Frequency view on genome changes testing].

Laboratories dealing with human genome, both inherited and acquired changes, dispose with similar methods and technology. The spectrum of genetic tests is relatively broad and the number of mutations or variants tested differs substantially. Also the number of examinations carried out in individual laboratories varies.

[Case reports of patients with a marker chromosome].

Small, usually supernumerary chromosomes, denoted as marker chromosomes or markers, can be represented by various phenotypic expression, that depends on their origin and extent. Our article presents results of molecular cytogenetic analysis (FISH) of 34 patients with identified marker chromosome. In 21 cases a marker derived from acrocentric chromosome was identified, in 9 cases markers of gonosomal origin [der(X), der(Y)], and in 4 patients markers of some other chromosomes (5, 17, 18) were proved.

Mutations in the human TBX4 gene cause small patella syndrome.

Small patella syndrome (SPS) is an autosomal-dominant skeletal dysplasia characterized by patellar aplasia or hypoplasia and by anomalies of the pelvis and feet, including disrupted ossification of the ischia and inferior pubic rami. We identified an SPS critical region of 5.6 cM on chromosome 17q22 by haplotype analysis.

[Detection of HER-2/neu in breast carcinoma].

Background: HER-2/neu protein overexpression has been shown to be an independently adverse prognostic and predictive factor in patients with breast cancer. Recently, HER-2/neu overexpression has gained therapeutic implications: It has been shown that in patients with breast cancer the use of trastuzumab/Herceptin TM, the recombinant humanized monoclonal antibody directed against extracellular domain of HER-2/neu molecule, can block the HER-2/neu protein activation and bring about a clinical remission. Following these developments, demand for pathologists to evaluating properly HER-2/neu in breast cancer specimens has been rapidly increasing.